Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonist

Edna Matta-Camacho1, Subhashis Banerjee1, Travis S Hughes1

  • 1From the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33418 and.

Insights

Nuclear receptors REV-ERBα/β bind heme. Unexpectedly, CoPP and ZnPP act as antagonists, not agonists, revealing subtle structural differences in ligand binding that impact REV-ERB function.

Area of Science:

  • Molecular Biology
  • Structural Biology
  • Biochemistry

Background:

  • REV-ERBα and REV-ERBβ are nuclear receptors regulating circadian rhythms, metabolism, and immunity.
  • Initially orphan receptors, they are now known to bind heme.
  • Understanding their ligand interactions is crucial for their physiological roles.

Purpose of the Study:

  • To investigate the structural basis for REV-ERBβ's differential response to heme, CoPP, and ZnPP.
  • To elucidate how subtle structural changes in porphyrin ligands affect REV-ERB antagonism or agonism.

Main Methods:

  • Biochemical assays
  • X-ray crystallography
  • Nuclear Magnetic Resonance (NMR) spectroscopy
  • Structural analysis of REV-ERBβ bound to heme, CoPP, and ZnPP.

Main Results:

  • CoPP and ZnPP bind directly to REV-ERBβ but act as antagonists, unlike heme.
  • Crystal structure of CoPP-bound REV-ERBβ shows minor conformational changes compared to heme-bound state.
  • CoPP's planar porphyrin ring conformation differs from heme's puckered conformation.

Conclusions:

  • Subtle changes in the porphyrin metal center and ring conformation dictate agonist versus antagonist activity.
  • Gas binding to heme's iron center may be key to altering REV-ERB activity.
  • These findings provide structural insights into REV-ERB ligand discrimination.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.5K
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.1K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
4.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.4K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.3K